Hims & Hers Health, Inc. (HIMS) trades on NYSE and is classified in the Healthcare sector. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers. This page tracks HIMS using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$29.71
Volume
10,989,081
52-week range
$13.74 – $65.30
Market cap
$6.93B
Source: Polygon (snapshot) · Verified Oct 14, 2026, 6:12 PM EDT
1D
-6.90%
1W
-6.16%
1M
-3.78%
1Y
-48.69%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Aug 9, 2026, 8:00 PM EDT
P/E (trailing)
Trailing earnings are negative, so a trailing P/E is not meaningful.
P/E (forward, est.)
Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Nov 1, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $753.2M · Diluted EPS -0.37
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | -0.37 | -0.01 | -2487.4% |
| 2026-03-31 | -0.19 | 0.04 | -529.9% |
| 2025-12-31 | 0.08 | 0.05 | +71.3% |
| 2025-09-30 | 0.06 | 0.11 | -43.6% |
Analysis based on data verified 2026-10-12T05:09:50.649+00:00. It has not been refreshed because current market inputs are not fresh enough. Based on data verified Oct 12, 2026, 1:09 AM EDT.
The bull case assumes Hims & Hers successfully evolves from a 'pill distributor' to a comprehensive health platform, leveraging its massive revenue growth to flip the switch on profitability and justify a premium valuation.
Hims & Hers is fairly valued at current levels, reflecting a high-growth business that is transitioning from a customer-acquisition phase to a profitability phase. The market is accurately pricing in the potential of its expanded product portfolio.
The bear case centers on the 'commodity' nature of generic drugs and the low barrier to entry for telehealth. If Hims cannot maintain its brand premium, the lack of current profitability becomes a structural failure rather than a temporary phase.
Calculated from verified reported financials and the last verified price (data verified Oct 12, 2026, 1:09 AM EDT). Analytical model output, not a price target or investment advice.
Rating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
22
Source: finnhub
GlobeNewswire · Oct 14, 2026
Yahoo Finance · Oct 14, 2026
Zacks Investment Research · Oct 14, 2026
Seeking Alpha · Oct 14, 2026
GlobeNewswire · Oct 13, 2026
Yahoo Finance · Oct 12, 2026
Some data is delayed, stale or unavailable. Everything shown is still verified.
Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health, Inc. trades under the ticker HIMS on NYSE.
HIMS was last verified at $27.66 (-6.90% on the day). After hours, last verified Oct 14, 2026, 6:12 PM EDT. Market data may be delayed and is shown with its own timestamp.
Based on the latest reported financials, HIMS revenue changed 38.2% year over year (filed Aug 9, 2026).
The next confirmed HIMS earnings date is Nov 1, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
For Q2'26, HIMS reported revenue of $753.2M and diluted EPS of -0.37.
Ticker-Terminal scores HIMS at 40/100 (F) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.
Create a free Ticker-Terminal account to run a full AI research report on HIMS — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from HIMS's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 14, 2026, 6:28 PM EDT.